Abstract
Standardized assessment instruments and direct observation data were collected pre-and postadministration (2 weeks after administration) on the effects of secretin on a 4-year-old boy diagnosed with autism. Information was collected on the three major diagnostic categories associated with autism: communication deficiencies, repetitive behavior and interests, and impaired social interactions. No changes in communication functioning, occurrences of stereotypic behavior, or social interaction were observed 2 weeks after administration of secretin. A 3-month follow-up interview with the child's primary care provider supported empirical data suggesting no substantial behavioral changes after the secretin administration. Results are discussed in terms of controversial treatments for children with autism and related developmental disorders.
Get full access to this article
View all access options for this article.